Hikma Pharmaceuticals Plc · LSE:HIK
Hikma Pharmaceuticals — Investor Presentation (September 2021)
27 slides from Hikma Pharmaceuticals's investor presentation, September 2021
Slide 1: Meet the Management Series – Generics
Better health. Within reach. Every day. Meet the Management Series – Generics September 2021
Slide 2: Disclaimer
Disclaimer Save to the extent required by law, neither Hikma Pharmaceuticals PLC nor any of its affiliates (Hikma), nor any other party, is under any duty to update or inform you of any changes to such information. In particular, it should be noted that the financial information relating to Hikma co
Slide 3: Agenda and speakers
Agenda and speakers 2:00 –2:05pm Welcome Siggi Olafsson 2:05 –2:25pm Business overview Brian Hoffmann Siggi Olafsson Brian Hoffmann CEO President 2:25 –2:35pm Operations and Quality Mike Balog 2:35 –2:45pm Commercial Kristy Ronco 2:45 –2:50pm Wrap up Brian Hoffmann Kristy Ronco Mike Balog 2:50 –3:30
Slide 4: Generics – A high value, growing asset
Generics – A high value, growing asset Injectables Generics Branded 2020 revenue 42% 32% 26% 2020 core operating profit contribution1 57% 24% 19% 1 Core operating profit is $566 million. Before unallocated corporate costs of $98 million and operating profit from Other business of zero, core operatin
Slide 5: Business overview
Business overview Brian Hoffmann President, Generics
Slide 6: Our Generics business today
Our Generics business today Top 10 generic non-injectable manufacturer Generics in the U.S.2 Differentiated generics and specialty 2020 revenue 32% brands driving significant value Customer- and patient-centricity are critical toward achieving our strategic ambitions 2020 core operating 24% >fourfol
Slide 7: Significant improvement in both top- and bottom-line
Significant improvement in both top- and bottom-line Generics financials ($m) Net Sales Core operating profit Core operating profit % $900 40% $810-$830 $800 $744 35% Acquired $719 Roxane Laboratories $692 $700 $615 30% $604 $600 22% 25% $500 22-24% 17% 20% $400 13% 15% $300 6% $161 10% $200 $151 4%
Slide 8: Delivering on promised business improvements
Delivering on promised business improvements 2018 Capital Markets Day Achievements 2021+ priorities Near-to-medium term priorities Long-term priorities • Sale of Eatontown manufacturing facility • Sold in 2018 • Maintain highest quality standards • Consolidate warehousing and distribution • Centrali
Slide 9: Maintaining balanced pipeline to deliver sustainable organic growth
Maintaining balanced pipeline to deliver sustainable organic growth Key pipeline metrics Development phase Dosage form Filing type 4% 1% 4% Respiratory Transdermal 30% 48% Nasal Development 4% 54% 46% Filed Opht../topical Non-p. IV p. IV 20% Liquid 22% 43% 22% IR oral solid Approved/TA ER oral solid
Slide 10: Attractive pipeline assets driving continued portfolio growth
Attractive pipeline assets driving continued portfolio growth Our disclosed pipeline programs Specialty Paragraph IV ANDAs Hikma product Filing type Potential U.S. Reference listed drug Potential U.S. Status (market comparator) (status) market size ($m)1 (molecule) market size ($m)1 Bilastine NDA Fa
Slide 11: Building robust Hikma Specialty branded portfolio
Building robust Hikma Specialty branded portfolio Hikma Specialty portfolio Infrastructure and growth strategy Call points: Primary Care Allergy / ENT Community Health Commercial • Building upon strong foundation with demonstrated success growing Mitigare®, despite late entry into a challenging mark
Slide 12: Investing in differentiated respiratory franchise
Investing in differentiated respiratory franchise 1 Fluticasone/salmeterol DPI 2 Generic Ellipta® portfolio • Successfully launched our generic Advair Diskus® • Collaboration with Vectura to develop AB-rated versions of at least three in April 2021 GSK Ellipta® products • Steadily gaining market sha
Slide 13: Generics strategic priorities
Generics strategic priorities Deliver more from a solid foundation Reduce COGS to drive Columbus towards top quartile in efficiency and productivity Build a culture of collaboration Increase capacity utilisation Create an environment where Better health. people can meet their full potential Improve
Slide 14: Operations & Quality
Operations & Quality Mike Balog SVP Operations, Generics
Slide 15: World-class infrastructure supporting Generics development and manufacturing
World-class infrastructure supporting Generics development and manufacturing Global capabilities Columbus, Ohio operations • Leading US-based generic, contract, and specialty manufacturer U.S. Jordan (Columbus, OH) (Amman, Sahab) • ~1,200 employees API • Wide range of dosage forms, including solids,
Slide 16: Our comprehensive manufacturing capabilities
Our comprehensive manufacturing capabilities Best in class operations Quality Efficiency Flexibility Capacity Capabilities Innovation Investment • Successful FDA and international Capacity utilisation Near-term investments regulatory body inspections • >6 billion equivalent tablets annually • Mainta
Slide 17: Quality is always our #1 priority
Quality is always our #1 priority An uncompromising commitment to quality is engrained in our culture Training partner to educate and train new and existing FDA employees Extensive track record of successful inspections from FDA and international regulatory bodies at four manufacturing sites Custome
Slide 18: Our in-house warehouse and distribution capabilities
Our in-house warehouse and distribution capabilities Creekside (Columbus, OH) distribution center Ideal location Greenfield site built in 2017 to consolidate U.S. warehousing and • Nearly 60% of the U.S. population is within 600 miles of Ohio1 distribution; allows us to: • Close proximity to key cus
Slide 19: Case study: Kloxxado acquisition through launch
Case study: Kloxxado acquisition through launch TM Kloxxado (naloxone HCl) nasal spray 8mg timeline TM August 2019 October 2019 April 2020 April 2021 Product acquisition Uninstall (AZ) / ship / Manufacture FDA complete reinstall (OH) lab equipment registration batches approval August 2021 September
Slide 20: Commercial
Commercial Kristy Ronco Chief Commercial Officer, Generics
Slide 21: Customer-centric go-to-market approach
Customer-centric go-to-market approach Generics customer landscape Commercial infrastructure Buying consortia Primary Allergy Community Generics care / ENT Health Base business Hikma Specialty Dedicated Synergies across division Key relationships • VP Sales • Manufacturing, Operations, Quality • Nat
Slide 22: Improving practices to become industry-leading supplier
Improving practices to become industry-leading supplier Focusing on the foundation Cross-functional coordination Delivering strong results We have been successful by In addition to new product launches, Impressive margin expansion in focusing on three key areas… effective Sales & Operations Planning
Slide 23: Bringing differentiated new products to market
Bringing differentiated new products to market Everolimus (gZortress) tabs Icosapent caps Generic Advair Diskus® Successful paragraph IV outcome, first to Demonstrates ability to successfully litigate Complex drug/device launch; market with over one year as sole generic paragraph IV filings and brin
Slide 24: Kloxxado launch bringing important new product to patients and caregivers
Kloxxado launch bringing important new product to patients and caregivers TM “Today’s action meets another critical need in combatting KloxxadoTM >93,000 deaths >30% of patients opioid overdose. Addressing the opioid crisis is a top priority addresses a major number of Americans who require at least
Slide 25: Wrap up
Wrap up Brian Hoffmann President, Generics
Slide 26: Leveraging our strengths to deliver sustainable growth
Leveraging our strengths to deliver sustainable growth Our Strategy: Our priorities: Operations Diversification & Expansion • Maintain highest quality standards • Maximise operational efficiency and • Increase portfolio of Continual year- capacity utilisation differentiated generic products Revenue
Slide 27: Generics Meet the Management - Q&A
Better health. Within reach. Every day. Generics Meet the Management - Q&A
Hikma Pharmaceuticals — Investor Presentation (September 2021) on 6ix